Storia in 7 fonti

FDA approves Bristol Myers’ multiple myeloma successor

FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo2 g fa

FDA approves Bristol Myers’ multiple myeloma successor

FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.

originale

Timeline cronologica

giovedì 13 agosto 2026·medpagetoday.com
FDA Approves First CELMoD Drug for Multiple Myeloma
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
giovedì 13 agosto 2026·morningstar.com
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for…

FDA approves Bristol Myers’ multiple myeloma successor

Confronto fonti

FDA approves Bristol Myers’ multiple myeloma successor

Timeline cronologica

FDA Approves First CELMoD Drug for Multiple Myeloma

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination…

FDA Approves First CELMoD Drug for Multiple Myeloma

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

FDA approves Bristol Myers’ multiple myeloma successor

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)